Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29985936 | 0.85 | DGAT1 (0.35) | DGAT1NPC1BRD4CREBBPMET | |
| SCHEMBL2611088 | 0.85 | MET (0.47) | DGAT1NPC1BRD4CREBBPMET | |
| SCHEMBL27628228 | 0.79 | LTA4H (0.43) | DGAT1BRD4CREBBPMAPT | |
| SCHEMBL3304410 | 0.78 | GSK3A (0.34) | DGAT1BRD4CREBBP | |
| SCHEMBL5952134 | 0.78 | FGFR1 (0.41) | DGAT1NPC1BRD4CREBBPMAPT | |
| SCHEMBL19538828 | 0.78 | BRD4 (0.46) | DGAT1NPC1BRD4CREBBPMAPT | |
| SCHEMBL1192428 | 0.77 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL30483953 | 0.76 | LTA4H (0.45) | DGAT1NPC1BRD4CREBBP | |
| SCHEMBL21474724 | 0.76 | LTA4H (0.45) | DGAT1NPC1BRD4CREBBP | |
| SCHEMBL5951458 | 0.74 | MEN1 (0.56) | NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450315-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8158626-B2 | Thiazolopyrimidine PI3K inhibitor compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-17 | — | — | US | disclosed |
| US-20110112085-A1 | THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110105464-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105464-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PIK3CB, PIK3C2B | DGAT1 1828/4885NPC1 1321/4885BRD4 2199/4885 |
| US-20110112085-A1 | THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | DGAT1 732/4885NPC1 668/4885BRD4 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.